Ixazomib safety study for people with multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This early-phase study tests how safe ixazomib is for people with multiple sclerosis (MS). It focuses on targeting certain immune cells in MS and checks whether the treatment can be given safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old
- You have MS, and your type of MS must match your MS medicines (RRMS needs a stable disease treatment; progressive MS must not use a disease treatment)
- If you have RRMS, you haven’t had an MS relapse in the last month and your spinal fluid test must be positive for “OCB”
- You must be able to give written consent and follow study instructions
- Your blood tests must be within limits (enough white cells and platelets, and acceptable liver and kidney function)
- You must use effective birth control (or be unable to get pregnant or father a child) during treatment and for 90 days after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This trial studies whether adding low-dose lenalidomide to ixazomib can help keep high-risk multiple myeloma from coming back after initial treatment. It may help prolong the time before the disease worsens, while also checking side effects.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This trial studies whether adding ixazomib (an oral drug) to a transplant using your own stem cells can control relapsed multiple myeloma better. It may help by strengthening anti-myeloma treatment after the transplant, aiming to delay disease progression.
This study tests an experimental pill called remibrutinib in people with multiple sclerosis (MS). It uses MRI scans to see how well the drug works at reducing MS activity. This could help people with relapsing or progressive MS.
Hear when a new Relapsing Remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.